LEGN — Legend Biotech Balance Sheet
0.000.00%
Last trade - 00:00- $6.29bn
- $5.52bn
- $627.24m
- 80
- 15
- 56
- 49
Annual balance sheet for Legend Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 20-F/A | 20-F/A | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 506 | 884 | 1,027 | 1,309 | 1,123 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 82.5 | 58.3 | 45.5 | 157 | 125 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 594 | 950 | 1,099 | 1,498 | 1,284 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 112 | 141 | 161 | 189 | 201 |
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 722 | 1,119 | 1,331 | 1,849 | 1,670 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 116 | 229 | 298 | 216 | 278 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 124 | 354 | 587 | 597 | 630 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 598 | 766 | 744 | 1,251 | 1,041 |
| Total Liabilities & Shareholders' Equity | 722 | 1,119 | 1,331 | 1,849 | 1,670 |
| Total Common Shares Outstanding |